These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 24491811)

  • 61. [The cancer paradigm in pulmonary arterial hypertension: towards anti-remodeling therapies targeting metabolic dysfunction?].
    Dumas SJ; Humbert M; Cohen-Kaminsky S
    Biol Aujourdhui; 2016; 210(4):171-189. PubMed ID: 28327277
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Immunotherapy for Pulmonary Arterial Hypertension: From the Pathogenesis to Clinical Management.
    Zhang Y; Li X; Li S; Zhou Y; Zhang T; Sun L
    Int J Mol Sci; 2024 Aug; 25(15):. PubMed ID: 39125996
    [TBL] [Abstract][Full Text] [Related]  

  • 63. The estrogen paradox in pulmonary arterial hypertension.
    Sakao S; Tanabe N; Tatsumi K
    Am J Physiol Lung Cell Mol Physiol; 2010 Oct; 299(4):L435-8. PubMed ID: 20656892
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Cellular and molecular basis of pulmonary arterial hypertension.
    Morrell NW; Adnot S; Archer SL; Dupuis J; Lloyd Jones P; MacLean MR; McMurtry IF; Stenmark KR; Thistlethwaite PA; Weissmann N; Yuan JX; Weir EK
    J Am Coll Cardiol; 2009 Jun; 54(1 Suppl):S20-S31. PubMed ID: 19555855
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Pulmonary arterial hypertension: New pathophysiological insights and emerging therapeutic targets.
    Bourgeois A; Omura J; Habbout K; Bonnet S; Boucherat O
    Int J Biochem Cell Biol; 2018 Nov; 104():9-13. PubMed ID: 30189252
    [TBL] [Abstract][Full Text] [Related]  

  • 66. CD39 in the development and progression of pulmonary arterial hypertension.
    Willcox A; Lee NT; Nandurkar HH; Sashindranath M
    Purinergic Signal; 2022 Dec; 18(4):409-419. PubMed ID: 35947229
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Endothelial Dysfunction in Pulmonary Hypertension: Cause or Consequence?
    Kurakula K; Smolders VFED; Tura-Ceide O; Jukema JW; Quax PHA; Goumans MJ
    Biomedicines; 2021 Jan; 9(1):. PubMed ID: 33435311
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Molecular pathogenesis and current pathology of pulmonary hypertension.
    de Jesus Perez VA
    Heart Fail Rev; 2016 May; 21(3):239-57. PubMed ID: 26694808
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inflammatory Mechanisms in the Pathogenesis of Pulmonary Arterial Hypertension: Recent Advances.
    Mercurio V; Cuomo A; Naranjo M; Hassoun PM
    Compr Physiol; 2021 Apr; 11(2):1805-1829. PubMed ID: 33792903
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Insights on the epigenetic mechanisms underlying pulmonary arterial hypertension.
    Luna RCP; de Oliveira Y; Lisboa JVC; Chaves TR; de Araújo TAM; de Sousa EE; Miranda Neto M; Pirola L; Braga VA; de Brito Alves JL
    Braz J Med Biol Res; 2018 Oct; 51(12):e7437. PubMed ID: 30365723
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension.
    Kim JD; Lee A; Choi J; Park Y; Kang H; Chang W; Lee MS; Kim J
    Exp Mol Med; 2015 Jul; 47(7):e175. PubMed ID: 26228095
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Perivascular Inflammation in Pulmonary Arterial Hypertension.
    Hu Y; Chi L; Kuebler WM; Goldenberg NM
    Cells; 2020 Oct; 9(11):. PubMed ID: 33105588
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A crucial role of endoplasmic reticulum stress in cellular responses during pulmonary arterial hypertension.
    Pan T; Zhang L; Miao K; Wang Y
    Am J Transl Res; 2020; 12(5):1481-1490. PubMed ID: 32509157
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pathology of pulmonary hypertension.
    Tuder RM; Stacher E; Robinson J; Kumar R; Graham BB
    Clin Chest Med; 2013 Dec; 34(4):639-50. PubMed ID: 24267295
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Promising therapeutic approaches in pulmonary arterial hypertension.
    Ali MK; Ichimura K; Spiekerkoetter E
    Curr Opin Pharmacol; 2021 Aug; 59():127-139. PubMed ID: 34217109
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Clinical Significance of the Sympathetic Nervous System in the Development and Progression of Pulmonary Arterial Hypertension.
    Liu RX; Luo Q; Qiao H; Yu J; Zhang QL; Wang P; Cao YG; Jiang CL; Qu LH
    Curr Neurovasc Res; 2017; 14(2):190-198. PubMed ID: 28088894
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Light at the ENDothelium-role of Sox17 and Runx1 in endothelial dysfunction and pulmonary arterial hypertension.
    Simmons Beck R; Liang OD; Klinger JR
    Front Cardiovasc Med; 2023; 10():1274033. PubMed ID: 38028440
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Inflammation, growth factors, and pulmonary vascular remodeling.
    Hassoun PM; Mouthon L; Barberà JA; Eddahibi S; Flores SC; Grimminger F; Jones PL; Maitland ML; Michelakis ED; Morrell NW; Newman JH; Rabinovitch M; Schermuly R; Stenmark KR; Voelkel NF; Yuan JX; Humbert M
    J Am Coll Cardiol; 2009 Jun; 54(1 Suppl):S10-S19. PubMed ID: 19555853
    [TBL] [Abstract][Full Text] [Related]  

  • 79. An emerging strategy for targeted therapy of pulmonary arterial hypertension: Vasodilation plus vascular remodeling inhibition.
    Hu L; Zhao C; Chen Z; Hu G; Li X; Li Q
    Drug Discov Today; 2022 May; 27(5):1457-1463. PubMed ID: 35104622
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Thrombosis, platelets, microparticles and PAH: more than a clot.
    Lannan KL; Phipps RP; White RJ
    Drug Discov Today; 2014 Aug; 19(8):1230-5. PubMed ID: 24747560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.